Moreover, TRAIL has been reported as an alternative therapeutic target for ovarian cancer management, although the targeted restriction of tyrosine kinase family proteins (PYK2 and FAK) and BCL-XL works synergistically and increases apoptosis in human ovarian carcinoma cell lines. This evidence concerns the gene TNFSF10 and ovarian cancer.